Humacyte, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Tue, November 10, 2026 at 4:59 PM EST 3 min read NVDA -4.99% HUMA +27.39% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth of 151% sequentially was driven by a complete remodeling of the commercial team, prioritizing professionals with deep, long-term relationships in the vascular surgery space.
Management attributed the 44% increase in hospital adoption to refined introductory pricing, incentive programs, and enhanced peer-to-peer professional education initiatives.
The commercial strategy focuses on converting initial hospital interest into approvals and sustained utilization by leveraging the trust built by the new leadership team.
Operational efficiency improved as research and development expenses declined sequentially due to the wind-down of certain programs and a reduction in noncommercial manufacturing runs.
The company successfully completed its first large-scale manufacturing lot of the CTEV product, demonstrating the scalability of its commercial-scale manufacturing facilities for pipeline expansion.
Strategic positioning in the trauma market serves as a foundational entry point, as the same vascular surgeons typically manage both trauma and future dialysis access cases.
Management expects fourth-quarter sales to at least double Q3 results, supported by current hospital adoption rates and physician agreement levels.
The supplemental BLA for ATEV in dialysis access is on track for submission in November 2026, with a potential PDUFA date in May 2027 if priority review is granted.
Future commercialization of the dialysis indication assumes a total addressable market of $2 billion to $3 billion annually in the U.S., targeting approximately 100,000 new patients per year.
Manufacturing plans for 2027 include a robust production schedule designed to eliminate unused capacity overhead and improve gross margins as commercial volume scales.
The company is developing health economic and reimbursement models to demonstrate total cost-of-care savings to Medicare and value-based care organizations ahead of the dialysis launch.
A $0.6 million net expense was recorded related to a reserve for the settlement of shareholder litigation and associated legal costs.
Cost of goods sold included $0.8 million in overhead related to unused production capacity, reflecting a strategic decision to limit production runs following high success rates in 2025.
The company maintains an RMAT designation for its ATEV product, which management believes justifies a priority review for the upcoming dialysis access filing.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Growth is driven by hiring leadership with established vascular surgery relationships and using introductory pricing to facilitate hospital evaluations.
Management expects the average selling price to strengthen as accounts transition from evaluation to sustained adoption.
There is significant overlap as approximately 80% of vascular surgeons using Symvess for trauma also perform dialysis access procedures.
This familiarity is expected to accelerate the adoption cycle for the dialysis indication upon approval.
Humacyte is partnering with value-based care organizations to model how ATEV can reduce total cost of care by improving optimal start metrics and reducing catheter-related complications.
While preclinical work continues, the company is currently prioritizing resources toward commercial scaling and the ATEV/CTEV clinical programs to manage cash flow and manufacturing capacity.
